Skip to main content
BIP logo

March 16, 2018

Internal newsletter of the Institut Pasteur

Institut Pasteur
  • Français
  • English
Press

First Subject Enrolled in Phase I Clinical Trial of its non-opioid analgesic STR-324

The Stragen group announced on March 13 the enrollment of the first subject to participate in a Phase I study of STR-324, a first in the class of non-opioid analgesic discovered by the Institut Pasteur. STR-324 is an endogenous peptide with proven efficacy in animal models. This clinical trial is a first-in-human study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of STR-324 in healthy subjects. The study is being carried out by the Centre for Human Drug Research in Leiden, the Netherlands, led by Principal Investigator Geert Jan Groeneveld, and is expected to enroll up to 78 subjects.

Read the press release

 

<<< Retour
  • BIP Archives
  • Contact